Business Wire

Adtran wins two FTTH Innovation Awards for 50G PON and deep PON fiber monitoring

27.3.2025 16:00:00 CET | Business Wire | Press release

Share

News summary: Adtran’s 50G PON fiber access solution and fiber monitoring platform recognized for their impact on advancing fiber broadband connectivity SDX 6405 OLT supports coexistence of GPON, XGS-PON and 50G PON on each port for seamless network scaling ALM with deep PON assurance delivers real-time, in-service fiber monitoring, enhancing network reliability and reducing opex costs

Adtran today announced that it has won two FTTH Innovation Awards at the FTTH Conference 2025, recognizing its SDX 6405 optical line terminal (OLT) and ALM fiber monitoring platform as standout technologies supporting next-generation fiber networks. Organized by the FTTH Council Europe, the annual awards highlight innovations that accelerate fiber broadband rollouts while improving scalability, operational efficiency and user experience. Adtran received awards in two categories: ‘Active infrastructure – central network’ and ‘Installation equipment, tools, test & measurement instruments.’

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326874284/en/

Adtran’s SDX 6405 OLT and ALM fiber monitoring platform received Innovation Awards at the FTTH Conference 2025.

“We’re honored to receive this recognition at the FTTH Conference. It’s a fantastic achievement for our team and a validation of the vision that’s guided our work: to help service providers build fiber networks that are open, scalable and ready for what comes next,” said Christoph Glingener, CTO of Adtran. “These wins reflect the dedication and expertise across our organization – from engineering to product to field support – and the close partnerships we’ve built with customers to solve real deployment challenges. Whether it’s enabling a future-proof transition to 50G PON or delivering affordable, real-time visibility into the access network, we’re focused on giving operators the tools to grow efficiently, improve reliability and stay ahead of demand.”

Adtran’s SDX 6405 won in the central network category for its 50G PON capabilities and disaggregated architecture. Part of the SDX 6000 Series, it supports GPON, XGS-PON and 50G PON on every port, enabling providers to deliver multigigabit services for residential, business and backhaul use cases – all over a single fiber. Its modular design eliminates the trade-off between near-term cost and long-term scalability. With the SDX 6405, providers can gradually add 50G OLTs to meet growing demand without disrupting existing subscribers or overhauling infrastructure. Built on an open, software-defined architecture, it integrates seamlessly into multivendor networks and supports automated service delivery through Adtran’s Mosaic Cloud Platform.

In the tools and measurement category, Adtran’s ALM was recognized for redefining how service providers monitor and manage fiber infrastructure. The compact, low-power device offers real-time, in-service visibility across the entire optical plant – enabling operators to detect and pinpoint issues before they affect customers. A key innovation is its deep PON assurance capability, which makes it possible to monitor fiber behind splitters without the need for demarcation reflectors. This is especially valuable for FTTH deployments, where scale and complexity can make fault detection and resolution a significant operational challenge. With support for fixed and mobile access networks, ALM empowers operators to increase service quality while lowering operational costs.

“These two awards recognize technologies that are solving critical challenges in access networks – from scaling bandwidth to ensuring new levels of service reliability,” commented Robert Conger, GM of software platforms and strategy at Adtran. “With 50G PON, we’re enabling a new generation of services that demand ultra-fast, highly reliable connectivity – whether that’s AI workloads, immersive experiences or industrial automation. At the same time, it delivers lower-speed services like 1G and 10G far more efficiently, helping operators simplify their access infrastructure and maximize return on investment. And with deep PON assurance, we’re giving operators the visibility they need to maintain those services at scale. It’s about building the foundation for sustainable, high-performance broadband that can evolve with demand.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326874284/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye